Yes, kidney disease is one of the most common causes of anemia. As kidney function declines, the body produces fewer red blood cells and has more trouble using iron effectively, leading to a progressive drop in hemoglobin. About 8% of people with the earliest stage of chronic kidney disease (CKD) have anemia, and that number climbs steeply: roughly 17% at stage 3, 50% at stage 4, and over 53% at stage 5.
Why Damaged Kidneys Lead to Anemia
Your kidneys do far more than filter waste. They also produce a protein called erythropoietin (EPO), which signals your bone marrow to make new red blood cells. Healthy kidneys sense when oxygen levels drop and ramp up EPO production in response. The cells responsible for making EPO are specialized cells that sit along tiny blood vessels inside the kidney.
In chronic kidney disease, those specialized cells gradually transform into scar-tissue cells called myofibroblasts. Once that happens, they lose the ability to produce EPO. With less EPO reaching the bone marrow, fewer red blood cells get made, and anemia develops. This is the primary driver of anemia in kidney disease, and it tends to worsen in step with kidney function.
Iron Gets Trapped in the Body
Low EPO is only part of the problem. Kidney disease also disrupts how your body handles iron, even if you’re getting enough from food. The key player here is a hormone called hepcidin, which controls how much iron enters your bloodstream from the gut and how much gets released from storage.
In CKD, two things push hepcidin levels abnormally high. First, chronic inflammation (common in kidney disease) directly stimulates hepcidin production. Second, diseased kidneys can’t clear hepcidin from the blood as efficiently, so it accumulates. The result: iron absorption from food slows down, and iron already stored in the body gets locked inside immune cells instead of being shuttled to bone marrow where red blood cells are assembled. You can have adequate iron stores on paper and still be functionally iron-deficient because the iron is trapped and unavailable.
For people on dialysis, the situation often gets worse. Catheters, dialysis membranes, and recurring infections add new sources of inflammation, pushing hepcidin even higher and deepening the iron problem.
Nutritional Factors That Compound the Problem
Kidney disease creates a hostile environment for nutrition in general. Acid buildup, chronic inflammation, hormonal imbalances, poor appetite, nausea, and slow digestion can all reduce intake of key nutrients. Folate and vitamin B12, both essential for healthy red blood cell production, can become depleted. Deficiencies in either one may worsen anemia or make it harder to treat. This is especially worth considering in people who are malnourished, have a history of heavy alcohol use, or aren’t responding well to standard anemia therapy.
Symptoms to Recognize
Anemia from kidney disease develops slowly, so many people don’t notice it at first. The symptoms overlap with general fatigue and can be easy to dismiss. According to the National Institute of Diabetes and Digestive and Kidney Diseases, common signs include:
- Fatigue or persistent tiredness
- Shortness of breath, especially with activity
- Unusually pale skin
- Weakness and body aches
- Dizziness or fainting
- Fast or irregular heartbeat
- Chest pain
- Headaches
- Trouble concentrating
- Sleep problems
Because these symptoms creep in gradually, many people adjust to feeling tired without realizing their hemoglobin has dropped significantly. Routine blood work is often what catches it.
How Anemia in Kidney Disease Is Diagnosed
Anemia is diagnosed through a simple blood test measuring hemoglobin, the oxygen-carrying protein in red blood cells. International guidelines define anemia in CKD as a hemoglobin below 13.0 g/dL in men and below 12.0 g/dL in women. These are the same thresholds used in the general population, but kidney doctors tend to monitor hemoglobin more frequently because of how predictably it drops as kidney function worsens.
Iron status also gets checked. Two key markers are ferritin (reflecting stored iron) and transferrin saturation, or TSAT (reflecting how much iron is actively available in the blood). In CKD, the thresholds used to flag iron deficiency are higher than normal because chronic inflammation skews the numbers. Ferritin below 100 mg/L in non-dialysis patients, or below 200 mg/L in dialysis patients, generally signals low iron stores. A TSAT below 20% suggests iron isn’t reaching the bone marrow adequately.
How It’s Treated
Treatment targets the two main problems: not enough EPO and not enough usable iron.
For the EPO shortage, doctors prescribe erythropoiesis-stimulating agents (ESAs), synthetic versions of the protein your kidneys can no longer make in sufficient quantities. These are given by injection, typically under the skin or through a dialysis line, and they stimulate bone marrow to produce more red blood cells. The goal is to raise hemoglobin enough to relieve symptoms and reduce the need for blood transfusions, without pushing it too high.
For the iron problem, oral iron supplements sometimes help in earlier stages, but because hepcidin blocks gut absorption, many CKD patients need intravenous iron delivered directly into the bloodstream. IV iron bypasses the absorption barrier entirely and makes iron immediately available to the bone marrow. Without adequate iron on board, ESAs don’t work nearly as well.
When folate or B12 deficiency is identified, supplementation can improve red blood cell production and help the body respond better to ESA therapy.
Why Treating Anemia Matters for the Heart
Untreated anemia in kidney disease isn’t just about feeling tired. It places real strain on the cardiovascular system. When hemoglobin is chronically low, the heart has to pump harder and faster to deliver enough oxygen to tissues. Over time, this extra workload causes the heart’s left ventricle to thicken and enlarge, a condition called left ventricular hypertrophy, or LVH. LVH is an independent risk factor for heart failure.
CKD already raises cardiovascular risk on its own through a combination of oxidative stress, fluid overload, and metabolic changes. Adding anemia to that picture magnifies the damage. The combination of oxidative stress and LVH in kidney disease significantly increases the risk of heart failure and sudden cardiac events. This is a major reason why kidney specialists monitor and treat anemia proactively rather than waiting for symptoms to become severe.